An improved intravesical model using human bladder cancer cell lines to optimize gene and other therapies
An improved intravesical model using human bladder cancer cell lines to optimize gene and other therapies
复制标题
DOI：
10.1038/sj.cgt.7700261
复制
发表时间：
2000-12-01
影响因子：
6.4
通讯作者：
Benedict, WF
中科院分区：
文献类型：
--
作者：
Watanabe, T;Shinohara, N;Benedict, WF
原位移植人膀胱癌细胞到免疫缺陷小鼠是研究生物学和治疗效果的重要工具。然而，通过经尿道滴注人膀胱癌细胞到鼠膀胱中的肿瘤植入和生长的发生率低或不可再现。然而，使用改良的膀胱内技术和人膀胱癌细胞系KU-7和UM-UC-2，我们已经能够获得浅表性膀胱肿瘤的高且可重复的发生率。此外，膀胱内施用LacZ腺病毒载体导致这些膀胱肿瘤以及正常尿路上皮中显著的β-半乳糖苷酶表达，这与糖氨基聚糖层的去除相关。由于这种改良的技术产生了高发生率的浅表肿瘤生长酸允许基因转移的疗效进行评估，它应该是一个有用的模型，研究膀胱内基因治疗的人膀胱癌。
Orthotopic implantation of human bladder cancer cells into immunodeficient mice is an important tool for studying the biology and effects of therapy. Nevertheless, the incidence of tumor implantation and growth by transurethral instillation of the human bladder cancer cells into murine bladders has been low or not reproducible. However, using a modified intravesical technique and the human bladder cancer cell lines, KU-7 and UM-UC-2, we have been able to obtain a high and reproducible incidence of superficial bladder tumors. Furthermore, intravesical administration of the LacZ adenovirus vector resulted in significant beta -galactosidase expression in these bladder tumors as well as the normal urothelium, which was associated with the removal of the glycosoaminoglycan layer. Because this modified technique produces a high incidence of superficial human tumor growth acid allows the efficacy of ge ne transfer to be evaluated, it should be a useful model for the study of intravesical gene therapy for human bladder cancer.